A 7-year-old male with relapsed/refractory acute myeloid leukemia was referred to St. Jude Children’s Research Hospital for enrollment in a phase I study of venetoclax in combination with chemotherapy (NCT03194932). On day 22 of treatment with venetoclax (days 1–28) and cytarabine (days 8–11), the patient was admitted for febrile neutropenia. Despite having received micafungin since day 1, blood cultures were positive for Candida krusei.